Stockreport

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented [Read more]